Watanabe et al., 2021 - Google Patents
Reduced deliquescency of isosorbide by cocrystallization and mechanisms for hygroscopicityWatanabe et al., 2021
- Document ID
- 8699542734057780143
- Author
- Watanabe T
- Ito M
- Suzuki H
- Terada K
- Noguchi S
- Publication year
- Publication venue
- International Journal of Pharmaceutics
External Links
Snippet
Isosorbide (ISO) is an effective hyperosmotic agent that can be administrated orally and is used as a therapeutic agent for brain pressure drop, glaucoma, and Meniere's disease. However, the critical relative humidity (CRH) of ISO is about 48% RH at 25° C, and it …
- 229960002479 Isosorbide 0 title abstract description 153
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl group being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-arylpropionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O-metal, -CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/265—Citric acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Watanabe et al. | Reduced deliquescency of isosorbide by cocrystallization and mechanisms for hygroscopicity | |
| Deng et al. | Dapagliflozin-citric acid cocrystal showing better solid state properties than dapagliflozin | |
| Nugrahani et al. | Zwitterionic cocrystal of diclofenac and L-proline: Structure determination, solubility, kinetics of cocrystallization, and stability study | |
| JP6328737B2 (en) | L-ornithine phenylacetate and process for producing the same | |
| EP3380456B1 (en) | Complex of angiotensin receptor antagonist and neutral endopeptidase inhibitor | |
| RU2603138C1 (en) | Crystalline form of hidamide, method of its production and use | |
| Roy et al. | Mechanochemical cocrystallization to improve the physicochemical properties of chlorzoxazone | |
| WO2012138907A2 (en) | Solid forms of curcumin | |
| EP4286377A1 (en) | Crystal form of resmetirom, preparation method therefor, and use thereof | |
| WO2021129465A1 (en) | Resmetirom crystal, preparation method for same, and uses thereof | |
| Xia et al. | Rucaparib cocrystal: Improved solubility and bioavailability over camsylate | |
| Xuan et al. | Impact of cocrystal solution-state stability on cocrystal dissociation and polymorphic drug recrystallization during dissolution | |
| Meng et al. | Preparation, characterization, and pharmacokinetics of rivaroxaban cocrystals with enhanced in vitro and in vivo properties in beagle dogs | |
| AU2012231547B2 (en) | New crystal form VII of agomelatine, preparation method and use thereof and pharmaceutical composition containing same | |
| CN103965116A (en) | Hemi-5-fluorocytosine salt, as well as preparation method and application thereof | |
| de Oliveira Junior et al. | A new crystalline ketoprofen sodium salt: Solid-state characterization, solubility, and stability | |
| EP2940026B1 (en) | Composition of glucose derivative and proline, crystal, preparation method and application | |
| CN112851726A (en) | Arbutin-carbamide eutectic crystal and preparation method, preparation and application thereof | |
| ES2926790T3 (en) | Sodium-glucose transporter inhibitor diethylamine solvate, and method of preparation and application thereof | |
| US20220251044A1 (en) | Crystal form of hypoxia-inducible factor-prolyl hydroxylase inhibitor | |
| CN105601589A (en) | Dipfluzine-p-hydroxybenzoic acid eutectic crystal and preparation method thereof | |
| US9468623B1 (en) | Medical use of compound from Garcinia esculenta | |
| Wang et al. | Pharmaceutical salt of isoniazid− orotic acid with optimized solubility, dissolution rate, and tabletability | |
| EA035346B1 (en) | 4-toluenesulfonic acid palbociclib salt, method for production thereof and use thereof in medicine | |
| CN117003701A (en) | Fluocytosine-isostearate and preparation method and application thereof |